Description: Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company, through its Tumorgraft Technology Platform, provides Personalized Oncology Solutions (POS) that assists physicians in developing personalized treatment options for cancer patients through tumor specific data obtained from drug panels and related personalized oncology services. It also offers POS products, including personalized tumor boards that are designed to provide access to oncologists with expertise in particular tumor types; and gene sequencing that analyzes the genetic makeup of patient's tumor for the purpose of identifying useful drugs. In addition, the company offers Translational Oncology Solutions (TOS), including a preclinical Tumorgraft platform to pharmaceutical and biotechnology companies that uses vivo studies, which rely on implanting multiple tumors from TumorBank in mice and testing the therapy of interest on tumors. Further, it provides a bank of tumors that are acquired, collected, processed, validated, and stored for the use in TOS. The company markets its products through Internet, word of mouth, and a network of sales force. It serves patients, physicians, and drug development companies. The company was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011 to reflect its new focus on developing technologies to personalize the development and use of oncology drugs. Champions Oncology, Inc. is headquartered in Hackensack, New Jersey.
Home Page: www.championsoncology.com
CSBR Technical Analysis
One University Plaza
Hackensack,
NJ
07601
United States
Phone:
201 808 8400
Officers
| Name | Title |
|---|---|
| Dr. Ronnie Morris M.D. | Pres, CEO & Director |
| Mr. David Barry Miller M.B.A. | Chief Financial Officer |
| Dr. Maria Mancini Ph.D. | Chief of Scientific Operations |
| Mr. David DeOrnellis BS, CMAR, CPIA, RLATG | Exec. VP of Global Laboratory Operations |
| Dr. Michael Ritchie M.B.A., Ph.D. | Chief Commercial Officer |
| Dr. Karin Abarca Heidemann Ph.D. | Exec. VP of Global Scientific Operations |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Life Sciences Tools & Services |
| GIC Sub-Industry: | Life Sciences Tools & Services |
| Forward PE: | 43.4783 |
|---|---|
| Trailing PE: | 436 |
| Price-to-Book MRQ: | 9.8273 |
| Price-to-Sales TTM: | 1.3785 |
| IPO Date: | 2003-01-10 |
| Fiscal Year End: | April |
| Full Time Employees: | 230 |